Advertisement

Cancer and Anticancer Agents

  • David Edwards
Chapter

Abstract

It is usually much easier to design chemotherapy for a disease when the origins and aetiology of the disease is known, but this is not possible in the case of cancer. Some affirm that because there are many types of cancer, presenting many different aetiologies, then there must be as many causes as there are types. Others, using the principle of Occam’s razor, consider that there must be an overall single cause of cancer and that the different aetiologies are due to the nature of the tissue in which the disease originates. It is now generally accepted that there must be a single or a very small number of different causes of cancer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

13.7 References and Further Reading

  1. Baserga, R. (1971). The Cell Cycle and Cancer, Marcel Dekker, New YorkGoogle Scholar
  2. Boesen, E. and Davis, W. (1969). Cytotoxic Drugs in the Treatment of Cancer. Edward Arnold, LondonGoogle Scholar
  3. Brule, G., Eckhardt, S. J., Hall, T. C. and Winkler, A. (1973). Drug Therapy of Cancer. World Health Organisation, GenevaGoogle Scholar
  4. Burnet, F. M. (1968). A modern basis for pathology. Lancet, 1, 1383–7CrossRefGoogle Scholar
  5. Burnet, F. M. (1970). Immunological Surveillance. Pergamon Press, OxfordCrossRefGoogle Scholar
  6. Cline, M. J. and Haskell, C. M. (1975). Cancer Chemotherapy. Saunders, PhiladelphiaGoogle Scholar
  7. Doll, R. (1977). Strategy for detection of cancer hazards to man. Nature, Lond., 265, 589–96CrossRefGoogle Scholar
  8. Edgar, J. A. (1974). Ascorbic acid and biological alkylating agents. Nature, Lond., 248, 136–7CrossRefGoogle Scholar
  9. Edwards, D. I. (1979). Cancer chemotherapy-new approaches. In Companion to the Life Sciences, Vol. 2 (S. Day, ed.). Van Nostrand-Rheinhold, New York (in press)Google Scholar
  10. Freifelder, D. and Levine, E. (1972). Stimulation of nuclease activity by thymine starvation. Biochem. biophys. Res. Commun., 46, 1782–7CrossRefGoogle Scholar
  11. Fuska, J. and Proska, B. (1976). Cytotoxic and antitumour antibiotics produced by microorganisms. Adv. appl. Microbiol, 20, 259–370CrossRefGoogle Scholar
  12. Ghose, T., Norvell, S. T., Gucla, A., Cameron, D., Bodurtha, A. and MacDonald, A. S. (1972). Immunotherapy of cancer with chlorambucil-carrying antibody. Br. med. J., 3, 495–9CrossRefGoogle Scholar
  13. Graham, F. L. and Whitamore, G. F. (1970). Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosyl cytosine-5-triphosphate. Cancer Res., 30, 2636–45Google Scholar
  14. Gregoriadis, G. (1977). Targeting of drugs. Nature, Lond., 265, 407–11CrossRefGoogle Scholar
  15. Guttenplan, J. B. (1977). Inhibition by L-ascorbate of bacterial mutagenesis induced by two N-nitroso compounds. Nature, Lond., 268, 368–70CrossRefGoogle Scholar
  16. Huebner, R. J. and Todaro, G. J. (1969). Oncogenes of RNA tumour viruses as determinants of cancer. Proc. natn. Acad. Sci., U.S.A., 64, 1087–94CrossRefGoogle Scholar
  17. Kitao, T. and Hattori, K. (1977). Concanavalin as a carrier of daunomycin. Nature, Lond., 265, 81–2CrossRefGoogle Scholar
  18. Nakayama, H. and Hanawalt, P. (1975). Sedimentation analysis of deoxyribonucleic acid from thymine-starved Escherichia coli. J. Bact., 121, 537–47Google Scholar
  19. Neidle, S. (1977). Approaches to effective anticancer drugs. Nature, Lond., 268, 195–6CrossRefGoogle Scholar
  20. Painter, R. B. (1977). Rapid test to detect agents that damage human DNA. Nature, Lond., 265, 650–1CrossRefGoogle Scholar
  21. Passwater, R. A. (1973). Cancer-new drections. Int. Lab., 10–19, July/AugustGoogle Scholar
  22. Pratt, W. B. (1973). Fundamentals of Chemotherapy. Oxford University Press, LondonGoogle Scholar
  23. Roy-Burman, P. (1970). Analogues of nucleic acids components. Mechanism of action. Recent Results cancer Res., 25, 1–106CrossRefGoogle Scholar
  24. Stutman, O. (1975). Immunosuppression and malignancy. Adv. Cancer Res., 22, 261–422CrossRefGoogle Scholar
  25. Tisdale, M. J. and Phillips, B. J. (1975). Inhibition of cyclic 3’,5’-nucleotide phosphodiesterase-a possible mechanism of action of bifunctional alkylating agents. Biochem. Pharmacol., 24, 211–7CrossRefGoogle Scholar
  26. Todrro, G. J., deLarco, J. E., Nissley, S. P. and Rechler, M. M. (1977). MSA and EGF receptors on sarcoma virus transferred cells and human fibrosarcoma cells in culture. Nature, Lond., 267, 526–8CrossRefGoogle Scholar
  27. Tovey, M. G., Begon-Lours, J., Gresser, I. and Morris, A. G. (1977). Marked enhancement of interferon production in 5-bromodeoxyuridine-treated human lymphoblastoid cells. Nature, Lond., 267, 455–6CrossRefGoogle Scholar
  28. Trouet, A., Campaneere, D. D. and de Duve, C. (1972). Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature new Biol., 239, 110–2CrossRefGoogle Scholar
  29. Wilson, L., Bryan, J., Ruby, A. and Mazia, D. (1970). Precipitation of proteins by vinblastine and calcium ions. Proc. natn. Acad. Sci. U.S.A., 66, 807–14CrossRefGoogle Scholar

Copyright information

© David Edwards 1980

Authors and Affiliations

  • David Edwards

There are no affiliations available

Personalised recommendations